Available by prescription only, mycophenolate is the active ingredient in two anti-rejection medications: CellCept® (mycophenolate mofetil) and Myfortic® (mycophenolate sodium).
These products contain different forms of mycophenolate, so they are not interchangeable. CellCept is approved to prevent organ rejection after a heart, kidney, or liver transplant, while Myfortic is only approved to prevent rejection in people who have received a kidney transplant.
CellCept comes in the form of tablets, capsules, and a liquid suspension. For people who cannot take it by mouth, an intravenous (IV) form is also available. As an immunosuppressant, it works by making the immune system less active, so it does not attack the new organ.
(For more information, click CellCept. This full-length article gives a complete overview of this medicine, with details on side effects, available strengths, what to do in cases of overdose, and more.)